Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study

Introduction: The efficacy and safety of subcutaneous (sc) pasireotide have been evaluated in a Phase III trial. Here, we report safety and efficacy results from a multinational, expanded-access study of pasireotide sc in patients with Cushing's disease (CD) in a real-world setting (clinicaltri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Endocrinol (Lausanne)
Autors principals: Fleseriu, Maria, Iweha, Chioma, Salgado, Luiz, Mazzuco, Tania Longo, Campigotto, Federico, Maamari, Ricardo, Limumpornpetch, Padiporn
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2019
Matèries:
Endocrinology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6646464/
https://ncbi.nlm.nih.gov/pubmed/31379734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2019.00436
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars